Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16672 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Takanori Suzuki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Interleukin-6, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Toyoaki Scholarship Foundation, Ichihara International Scholarship Foundation.
Abstract (Originalsprache)
Background and Aim Serum interleukin‐6 (IL‐6) before the administration of atezolizumab plus bevacizumab (Atez + Bev) is a prognostic biomarker in patients with hepatocellular carcinoma (HCC) treated with Atez + Bev. We previously revealed that the neutrophil‐to‐lymphocyte ratio and serum chemokine levels during treatment with Atez + Bev were more useful as prognostic biomarkers. Therefore, we examined the predictive ability of serum IL‐6 for the efficacy of Atez + Bev in patients with HCC.
Methods
We enrolled 94 patients with HCC who received treatment with Atez + Bev. Initial responses were assessed through dynamic computed tomography or magnetic resonance imaging. The levels of IL‐6 in serum were measured before and at the initiation of the second course of Atez + Bev. Subsequently, the relationship of IL‐6 levels with treatment efficacy was evaluated.
Results
IL‐6 levels at the initiation of the second course tended to be higher in patients with progressive disease versus those with non‐progressive disease in the initial evaluation ( P = 0.054). Moreover, the cutoff value (7.4 pg/mL) was useful in stratifying patients by overall survival (i.e. low vs high: not reached vs 21.4 months, respectively, P = 0.001) and progression‐free survival (low vs high: 11.9 vs 5.2 months, respectively, P = 0.004). This result was reproduced in patients with HCC who received Atez + Bev as first‐line therapy. In the multivariate analyses, IL‐6 levels at the initiation of the second course were independent predictive factors for progression‐free and overall survival.
Conclusions
Serum levels of IL‐6 at the initiation of the second course of treatment may predict Atez + Bev efficacy and prognosis in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Gifu, Japan.
- Department of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.
- Department of Gastroenterology, Toyokawa City Hospital, Toyokawa, Japan.
- Department of Gastroenterology, Nagoya City University West Medical Center, Nagoya, Japan.
- Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
ORCID-Profile: Kentaro Matsuura, Yasuhito Tanaka
Förderung
- Japan Society for the Promotion of Science
- Toyoaki Scholarship Foundation
- Ichihara International Scholarship Foundation
Zitieren
APA
Suzuki, T., Matsuura, K., Suzuki, Y., Okumura, F., Nagura, Y., Sobue, S., Matoya, S., Miyaki, T., Kimura, Y., Kusakabe, A., Narahara, S., Tokunaga, T., Nagaoka, K., Murakami, S., Inoue, T., Kuroyanagi, K., Kawamura, H., Fujiwara, K., Nojiri, S., …, & Tanaka, Y. (2024). Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16672
Vancouver
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, et al. Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16672
BibTeX
@article{Suzuki2024,
author = {Suzuki, Takanori and Matsuura, Kentaro and Suzuki, Yuta and Okumura, Fumihiro and Nagura, Yoshihito and Sobue, Satoshi and Matoya, Sho and Miyaki, Tomokatsu and Kimura, Yoshihide and Kusakabe, Atsunori and Narahara, Satoshi and Tokunaga, Takayuki and Nagaoka, Katsuya and Murakami, Shuko and Inoue, Takako and Kuroyanagi, Keita and Kawamura, Hayato and Fujiwara, Kei and Nojiri, Shunsuke and Kataoka, Hiromi and Tanaka, Yasuhito},
title = {Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16672}
}
EUVIMED